These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34366199)

  • 1. Stable, high yield expression of gp145 Env glycoprotein from HIV-1 in mammalian cells.
    Luthra A; Cheema S; Whitney S; Bakker WAM; Sandalon Z; Richardson J; Yallop C; Havenga M
    Biologicals; 2021 Sep; 73():16-23. PubMed ID: 34366199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.
    Wieczorek L; Krebs SJ; Kalyanaraman V; Whitney S; Tovanabutra S; Moscoso CG; Sanders-Buell E; Williams C; Slike B; Molnar S; Dussupt V; Alam SM; Chenine AL; Tong T; Hill EL; Liao HX; Hoelscher M; Maboko L; Zolla-Pazner S; Haynes BF; Pensiero M; McCutchan F; Malek-Salehi S; Cheng RH; Robb ML; VanCott T; Michael NL; Marovich MA; Alving CR; Matyas GR; Rao M; Polonis VR
    J Virol; 2015 Aug; 89(15):7478-93. PubMed ID: 25972551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses.
    Perdiguero B; Sánchez-Corzo C; Sorzano COS; Saiz L; Mediavilla P; Esteban M; Gómez CE
    Viruses; 2019 Feb; 11(2):. PubMed ID: 30781504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US.
    Tieu HV; Karuna S; Huang Y; Sobieszczyk ME; Zheng H; Tomaras GD; Montefiori DC; Shen M; DeRosa S; Cohen K; Isaacs MB; Regenold S; Heptinstall J; Seaton KE; Sawant S; Furch B; Pensiero M; Corey L; Bar KJ;
    Vaccine; 2023 Oct; 41(42):6309-6317. PubMed ID: 37679276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A recombinant gp145 Env glycoprotein from HIV-1 expressed in two different cell lines: Effects on glycosylation and antigenicity.
    González-Feliciano JA; Akamine P; Capó-Vélez CM; Delgado-Vélez M; Dussupt V; Krebs SJ; Wojna V; Polonis VR; Baerga-Ortiz A; Lasalde-Dominicci JA
    PLoS One; 2020; 15(6):e0231679. PubMed ID: 32559193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies.
    Chung NP; Matthews K; Kim HJ; Ketas TJ; Golabek M; de Los Reyes K; Korzun J; Yasmeen A; Sanders RW; Klasse PJ; Wilson IA; Ward AB; Marozsan AJ; Moore JP; Cupo A
    Retrovirology; 2014 Apr; 11():33. PubMed ID: 24767177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate.
    Sneha Priya R; Veena M; Kalisz I; Whitney S; Priyanka D; LaBranche CC; Sri Teja M; Montefiori DC; Pal R; Mahalingam S; Kalyanaraman VS
    J Biol Chem; 2015 Apr; 290(14):9195-208. PubMed ID: 25691567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.
    Wen Y; Trinh HV; Linton CE; Tani C; Norais N; Martinez-Guzman D; Ramesh P; Sun Y; Situ F; Karaca-Griffin S; Hamlin C; Onkar S; Tian S; Hilt S; Malyala P; Lodaya R; Li N; Otten G; Palladino G; Friedrich K; Aggarwal Y; LaBranche C; Duffy R; Shen X; Tomaras GD; Montefiori DC; Fulp W; Gottardo R; Burke B; Ulmer JB; Zolla-Pazner S; Liao HX; Haynes BF; Michael NL; Kim JH; Rao M; O'Connell RJ; Carfi A; Barnett SW
    PLoS One; 2018; 13(4):e0194266. PubMed ID: 29698406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers.
    Go EP; Ding H; Zhang S; Ringe RP; Nicely N; Hua D; Steinbock RT; Golabek M; Alin J; Alam SM; Cupo A; Haynes BF; Kappes JC; Moore JP; Sodroski JG; Desaire H
    J Virol; 2017 May; 91(9):. PubMed ID: 28202756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity comparison between codon optimized HIV-1 CRF BC_07 gp140 and gp145 vaccines.
    Liu L; Wan Y; Xu J; Huang X; Wu L; Liu Y; Shao Y
    AIDS Res Hum Retroviruses; 2007 Nov; 23(11):1396-404. PubMed ID: 18184083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140.
    Emmer KL; Wieczorek L; Tuyishime S; Molnar S; Polonis VR; Ertl HC
    AIDS; 2016 Oct; 30(16):2405-2414. PubMed ID: 27525550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines.
    Sharma VA; Kan E; Sun Y; Lian Y; Cisto J; Frasca V; Hilt S; Stamatatos L; Donnelly JJ; Ulmer JB; Barnett SW; Srivastava IK
    Virology; 2006 Aug; 352(1):131-44. PubMed ID: 21894641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene editing in CHO cells to prevent proteolysis and enhance glycosylation: Production of HIV envelope proteins as vaccine immunogens.
    Li SW; Wright M; Healey JF; Hutchinson JM; O'Rourke S; Mesa KA; Lollar P; Berman PW
    PLoS One; 2020; 15(5):e0233866. PubMed ID: 32470085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses.
    Perdiguero B; Gómez CE; García-Arriaza J; Sánchez-Corzo C; Sorzano CÓS; Wilmschen S; von Laer D; Asbach B; Schmalzl C; Peterhoff D; Ding S; Wagner R; Kimpel J; Levy Y; Pantaleo G; Esteban M
    Front Immunol; 2019; 10():2941. PubMed ID: 31921191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A reversed phase HPLC method for the quantification of HIV gp145 glycoprotein levels from cell culture supernatants.
    González-Feliciano JA; Capó-Vélez CM; Akamine P; Delgado-Vélez M; Almodóvar R; Rivera J; Pino I; Morell G; Eichinger D; Rivera JH; Lasalde-Dominicci JA; Baerga-Ortiz A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Mar; 1167():122562. PubMed ID: 33571843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycan Profiles of gp120 Protein Vaccines from Four Major HIV-1 Subtypes Produced from Different Host Cell Lines under Non-GMP or GMP Conditions.
    Wang S; Voronin Y; Zhao P; Ishihara M; Mehta N; Porterfield M; Chen Y; Bartley C; Hu G; Han D; Wells L; Tiemeyer M; Lu S
    J Virol; 2020 Mar; 94(7):. PubMed ID: 31941770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.
    Srivastava IK; Stamatatos L; Kan E; Vajdy M; Lian Y; Hilt S; Martin L; Vita C; Zhu P; Roux KH; Vojtech L; C Montefiori D; Donnelly J; Ulmer JB; Barnett SW
    J Virol; 2003 Oct; 77(20):11244-59. PubMed ID: 14512572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broad HIV-1 neutralizing antibody response induced by heterologous gp140/gp145 DNA prime-vaccinia boost immunization.
    Liu L; Hao Y; Luo Z; Huang Y; Hu X; Liu Y; Shao Y
    Vaccine; 2012 Jun; 30(28):4135-43. PubMed ID: 22561314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate.
    Dey AK; Cupo A; Ozorowski G; Sharma VK; Behrens AJ; Go EP; Ketas TJ; Yasmeen A; Klasse PJ; Sayeed E; Desaire H; Crispin M; Wilson IA; Sanders RW; Hassell T; Ward AB; Moore JP
    Biotechnol Bioeng; 2018 Apr; 115(4):885-899. PubMed ID: 29150937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing the Production of gp145, an HIV-1 Envelope Glycoprotein Vaccine Candidate and Its Encapsulation in Guanosine Microparticles.
    Akamine P; González-Feliciano JA; Almodóvar R; Morell G; Rivera J; Capó-Vélez CM; Delgado-Vélez M; Prieto-Costas L; Madera B; Eichinger D; Pino I; Rivera JH; Ortiz-Ubarri J; Rivera JM; Baerga-Ortiz A; Lasalde-Dominicci JA
    Vaccines (Basel); 2023 May; 11(5):. PubMed ID: 37243079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.